content: <PAGE>
                    SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  
  
  Date  of  Report  (Date of earliest event reported)       JUNE 24, 1996 
   
                                              ENZON, INC.
  
                    (Exact  name  of  registrant  as  specified  in its charter)
  
  
  
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
       (Former name or former address, if changed since last report)
  
  
  
  
  
  
  <PAGE>
  ITEM 5.  OTHER EVENTS
  
            Enzon,  Inc. ("Enzon" or the "Company") announced that  a  multi-
  dose, multi-center  clinical  trial of its hemoglobin-based oxygen carrier,
  PEG-hemoglobin, has begun in cancer  patients  receiving radiation therapy.
  Patients entering this new trial will receive once-a-week infusions of PEG-
  hemoglobin  followed  by five days of radiation treatment.   This  will  be
  repeated weekly for three  weeks.   The primary purpose of this trial is to
  evaluate safety related to multiple doses  of  PEG-hemoglobin  in patients.
  It  also  offers  an  opportunity  to  observe  tumor responses in patients
  receiving  the  combination  of PEG-hemoglobin and radiation  therapy.   To
  date, as many as three injections  of PEG-hemoglobin have been administered
  to patients participating in this clinical trial.
  
            In a previous Phase I safety trial, completed at the end of 1995,
  34 normal volunteers received a single dose of PEG-hemoglobin in amounts up
  to the equivalent of 1.5 units of whole  blood.  The dose levels in the new
  trial will be approximately one-half to two-thirds of the highest dose used
  in the previous Phase I safety trial.  The  Company  believes that, at this
  dose level, a sufficient amount of PEG-hemoglobin will  remain in the blood
  stream to increase tumor oxygenation during most of each five-day treatment
  cycle.
  
            Enzon  continues  to dedicate its pilot manufacturing  capability
  exclusively to the production  of  PEG-hemoglobin  for  additional clinical
  materials and commercial process development.  The existing facility at the
  present scale is adequate to supply all PEG-hemoglobin needed  for clinical
  trials.
  <PAGE>
  
  
  
                              SIGNATURES
  
  
       Pursuant to the requirements of the Securities Exchange Act  of  1934,
  
  the  Registrant  has  duly caused this report to be signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  
  
  
  Dated:  July 22, 1996
  
  
  
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 3358}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "96597228"}, "business-address": {"street1": "20 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  Date  of  Report  (Date of earliest event reported)       JUNE 24, 1996 
   
                                              ENZON, INC.
  
                    (Exact  name  of  registrant  as  specified  in its charter)
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
       (Former name or former address, if changed since last report)
  ITEM 5.  OTHER EVENTS
  
            Enzon,  Inc. ("Enzon" or the "Company") announced that  a  multi-
  dose, multi-center  clinical  trial of its hemoglobin-based oxygen carrier,
  PEG-hemoglobin, has begun in cancer  patients  receiving radiation therapy.
  Patients entering this new trial will receive once-a-week infusions of PEG-
  hemoglobin  followed  by five days of radiation treatment.   This  will  be
  repeated weekly for three  weeks.   The primary purpose of this trial is to
  evaluate safety related to multiple doses  of  PEG-hemoglobin  in patients.
  It  also  offers  an  opportunity  to  observe  tumor responses in patients
  receiving  the  combination  of PEG-hemoglobin and radiation  therapy.   To
  date, as many as three injections  of PEG-hemoglobin have been administered
  to patients participating in this clinical trial.
  
            In a previous Phase I safety trial, completed at the end of 1995,
  34 normal volunteers received a single dose of PEG-hemoglobin in amounts up
  to the equivalent of 1.5 units of whole  blood.  The dose levels in the new
  trial will be approximately one-half to two-thirds of the highest dose used
  in the previous Phase I safety trial.  The  Company  believes that, at this
  dose level, a sufficient amount of PEG-hemoglobin will  remain in the blood
  stream to increase tumor oxygenation during most of each five-day treatment
  cycle.
  
            Enzon  continues  to dedicate its pilot manufacturing  capability
  exclusively to the production  of  PEG-hemoglobin  for  additional clinical
  materials and commercial process development.  The existing facility at the
  present scale is adequate to supply all PEG-hemoglobin needed  for clinical
  trials.
  SIGNATURES
  
       Pursuant to the requirements of the Securities Exchange Act  of  1934,
  
  the  Registrant  has  duly caused this report to be signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  Dated:  July 22, 1996
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer